Global Long-Acting HIV-1 Inhibitors Market Growth (Status and Outlook) 2026-2032
The global Long-Acting HIV-1 Inhibitors market size is predicted to grow from US$ 373 million in 2025 to US$ 510 million in 2032; it is expected to grow at a CAGR of 4.7% from 2026 to 2032.
Long-Acting HIV-1 Inhibitors represent a class of antiretroviral formulations that utilize innovative pharmaceutical technologies (e.g., nanocrystals, liposomal encapsulation, or prodrug design) to extend drug duration in the body, with the primary goal of transitioning from daily oral dosing to dosing intervals of weeks or months. These medications maintain stable drug concentrations to sustainably suppress viral replication, significantly improving patient adherence and reducing side effects, particularly suitable for long-term HIV management and pre-exposure prophylaxis (PrEP). Current formulations include intramuscular injections, subcutaneous implants, and extended-release oral dosage forms, with technological barriers primarily lying in complex drug delivery system design and controlled release kinetics.
From a supply chain perspective, the upstream sector involves the supply of high-purity active pharmaceutical ingredients (APIs), specialty excipients (e.g., biodegradable polymers, stabilizers), and advanced packaging materials (e.g., pre-filled syringes). The midstream encompasses complex formulation development (including pharmacokinetic studies and stability testing), sterile manufacturing under GMP standards, and rigorous quality control systems. Downstream distribution occurs through specialized pharmaceutical logistics channels, disease control centers, and designated pharmacies to reach end patients, requiring?? professional healthcare training and usage guidance. Key supply chain challenges include ensuring stable supply of specialty excipients, meeting cold chain logistics requirements, and navigating complex multinational regulatory compliance, necessitating interdisciplinary technology integration and global collaboration capabilities.
United States market for Long-Acting HIV-1 Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Long-Acting HIV-1 Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Long-Acting HIV-1 Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Long-Acting HIV-1 Inhibitors players cover GSK, Frontier Biotechnologies, Gilead Sciences, ViiV Healthcare, Johnson & Johnson, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
This Insight Report provides a comprehensive analysis of the global Long-Acting HIV-1 Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Long-Acting HIV-1 Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-Acting HIV-1 Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-Acting HIV-1 Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-Acting HIV-1 Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of Long-Acting HIV-1 Inhibitors market by product type, application, key players and key regions and countries.
Long-Acting HIV-1 Inhibitors represent a class of antiretroviral formulations that utilize innovative pharmaceutical technologies (e.g., nanocrystals, liposomal encapsulation, or prodrug design) to extend drug duration in the body, with the primary goal of transitioning from daily oral dosing to dosing intervals of weeks or months. These medications maintain stable drug concentrations to sustainably suppress viral replication, significantly improving patient adherence and reducing side effects, particularly suitable for long-term HIV management and pre-exposure prophylaxis (PrEP). Current formulations include intramuscular injections, subcutaneous implants, and extended-release oral dosage forms, with technological barriers primarily lying in complex drug delivery system design and controlled release kinetics.
From a supply chain perspective, the upstream sector involves the supply of high-purity active pharmaceutical ingredients (APIs), specialty excipients (e.g., biodegradable polymers, stabilizers), and advanced packaging materials (e.g., pre-filled syringes). The midstream encompasses complex formulation development (including pharmacokinetic studies and stability testing), sterile manufacturing under GMP standards, and rigorous quality control systems. Downstream distribution occurs through specialized pharmaceutical logistics channels, disease control centers, and designated pharmacies to reach end patients, requiring?? professional healthcare training and usage guidance. Key supply chain challenges include ensuring stable supply of specialty excipients, meeting cold chain logistics requirements, and navigating complex multinational regulatory compliance, necessitating interdisciplinary technology integration and global collaboration capabilities.
United States market for Long-Acting HIV-1 Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Long-Acting HIV-1 Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Long-Acting HIV-1 Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Long-Acting HIV-1 Inhibitors players cover GSK, Frontier Biotechnologies, Gilead Sciences, ViiV Healthcare, Johnson & Johnson, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
Report Scope
LPI (LP Information)' newest research report, the “Long-Acting HIV-1 Inhibitors Industry Forecast” looks at past sales and reviews total world Long-Acting HIV-1 Inhibitors sales in 2025, providing a comprehensive analysis by region and market sector of projected Long-Acting HIV-1 Inhibitors sales for 2026 through 2032. With Long-Acting HIV-1 Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-Acting HIV-1 Inhibitors industry.This Insight Report provides a comprehensive analysis of the global Long-Acting HIV-1 Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Long-Acting HIV-1 Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-Acting HIV-1 Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-Acting HIV-1 Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-Acting HIV-1 Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of Long-Acting HIV-1 Inhibitors market by product type, application, key players and key regions and countries.
Market Segmentation
Segmentation by Type:
- Long-Acting Injection
- Long-Acting Oral
Segmentation by Application:
- Hospital
- Clinic
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- GSK
- Frontier Biotechnologies
- Gilead Sciences
- ViiV Healthcare
- Johnson & Johnson
- MSD
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Long-Acting HIV-1 Inhibitors Market Size (2021-2032)
2.1.2 Long-Acting HIV-1 Inhibitors Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Long-Acting HIV-1 Inhibitors by Country/Region (2021, 2025 & 2032)
2.2 Long-Acting HIV-1 Inhibitors Segment by Type
2.2.1 Long-Acting Injection
2.2.2 Long-Acting Oral
2.2.3 Long-Acting HIV-1 Inhibitors Market Size by Type
2.2.3.1 Long-Acting HIV-1 Inhibitors Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global Long-Acting HIV-1 Inhibitors Market Size Market Share by Type (2021-2026)
2.3 Long-Acting HIV-1 Inhibitors Segment by Application
2.3.1 Hospital
2.3.2 Clinic
2.3.3 Others
2.3.4 Long-Acting HIV-1 Inhibitors Market Size by Application
2.3.4.1 Long-Acting HIV-1 Inhibitors Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global Long-Acting HIV-1 Inhibitors Market Size Market Share by Application (2021-2026)
3 LONG-ACTING HIV-1 INHIBITORS MARKET SIZE BY PLAYER
3.1 Long-Acting HIV-1 Inhibitors Market Size Market Share by Player
3.1.1 Global Long-Acting HIV-1 Inhibitors Revenue by Player (2021-2026)
3.1.2 Global Long-Acting HIV-1 Inhibitors Revenue Market Share by Player (2021-2026)
3.2 Global Long-Acting HIV-1 Inhibitors Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 LONG-ACTING HIV-1 INHIBITORS BY REGION
4.1 Long-Acting HIV-1 Inhibitors Market Size by Region (2021-2026)
4.2 Global Long-Acting HIV-1 Inhibitors Annual Revenue by Country/Region (2021-2026)
4.3 Americas Long-Acting HIV-1 Inhibitors Market Size Growth (2021-2026)
4.4 APAC Long-Acting HIV-1 Inhibitors Market Size Growth (2021-2026)
4.5 Europe Long-Acting HIV-1 Inhibitors Market Size Growth (2021-2026)
4.6 Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Long-Acting HIV-1 Inhibitors Market Size by Country (2021-2026)
5.2 Americas Long-Acting HIV-1 Inhibitors Market Size by Type (2021-2026)
5.3 Americas Long-Acting HIV-1 Inhibitors Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Long-Acting HIV-1 Inhibitors Market Size by Region (2021-2026)
6.2 APAC Long-Acting HIV-1 Inhibitors Market Size by Type (2021-2026)
6.3 APAC Long-Acting HIV-1 Inhibitors Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Long-Acting HIV-1 Inhibitors Market Size by Country (2021-2026)
7.2 Europe Long-Acting HIV-1 Inhibitors Market Size by Type (2021-2026)
7.3 Europe Long-Acting HIV-1 Inhibitors Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Long-Acting HIV-1 Inhibitors by Region (2021-2026)
8.2 Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size by Type (2021-2026)
8.3 Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL LONG-ACTING HIV-1 INHIBITORS MARKET FORECAST
10.1 Global Long-Acting HIV-1 Inhibitors Forecast by Region (2027-2032)
10.1.1 Global Long-Acting HIV-1 Inhibitors Forecast by Region (2027-2032)
10.1.2 Americas Long-Acting HIV-1 Inhibitors Forecast
10.1.3 APAC Long-Acting HIV-1 Inhibitors Forecast
10.1.4 Europe Long-Acting HIV-1 Inhibitors Forecast
10.1.5 Middle East & Africa Long-Acting HIV-1 Inhibitors Forecast
10.2 Americas Long-Acting HIV-1 Inhibitors Forecast by Country (2027-2032)
10.2.1 United States Market Long-Acting HIV-1 Inhibitors Forecast
10.2.2 Canada Market Long-Acting HIV-1 Inhibitors Forecast
10.2.3 Mexico Market Long-Acting HIV-1 Inhibitors Forecast
10.2.4 Brazil Market Long-Acting HIV-1 Inhibitors Forecast
10.3 APAC Long-Acting HIV-1 Inhibitors Forecast by Region (2027-2032)
10.3.1 China Long-Acting HIV-1 Inhibitors Market Forecast
10.3.2 Japan Market Long-Acting HIV-1 Inhibitors Forecast
10.3.3 Korea Market Long-Acting HIV-1 Inhibitors Forecast
10.3.4 Southeast Asia Market Long-Acting HIV-1 Inhibitors Forecast
10.3.5 India Market Long-Acting HIV-1 Inhibitors Forecast
10.3.6 Australia Market Long-Acting HIV-1 Inhibitors Forecast
10.4 Europe Long-Acting HIV-1 Inhibitors Forecast by Country (2027-2032)
10.4.1 Germany Market Long-Acting HIV-1 Inhibitors Forecast
10.4.2 France Market Long-Acting HIV-1 Inhibitors Forecast
10.4.3 UK Market Long-Acting HIV-1 Inhibitors Forecast
10.4.4 Italy Market Long-Acting HIV-1 Inhibitors Forecast
10.4.5 Russia Market Long-Acting HIV-1 Inhibitors Forecast
10.5 Middle East & Africa Long-Acting HIV-1 Inhibitors Forecast by Region (2027-2032)
10.5.1 Egypt Market Long-Acting HIV-1 Inhibitors Forecast
10.5.2 South Africa Market Long-Acting HIV-1 Inhibitors Forecast
10.5.3 Israel Market Long-Acting HIV-1 Inhibitors Forecast
10.5.4 Turkey Market Long-Acting HIV-1 Inhibitors Forecast
10.6 Global Long-Acting HIV-1 Inhibitors Forecast by Type (2027-2032)
10.7 Global Long-Acting HIV-1 Inhibitors Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Long-Acting HIV-1 Inhibitors Forecast
11 KEY PLAYERS ANALYSIS
11.1 GSK
11.1.1 GSK Company Information
11.1.2 GSK Long-Acting HIV-1 Inhibitors Product Offered
11.1.3 GSK Long-Acting HIV-1 Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 GSK Main Business Overview
11.1.5 GSK Latest Developments
11.2 Frontier Biotechnologies
11.2.1 Frontier Biotechnologies Company Information
11.2.2 Frontier Biotechnologies Long-Acting HIV-1 Inhibitors Product Offered
11.2.3 Frontier Biotechnologies Long-Acting HIV-1 Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Frontier Biotechnologies Main Business Overview
11.2.5 Frontier Biotechnologies Latest Developments
11.3 Gilead Sciences
11.3.1 Gilead Sciences Company Information
11.3.2 Gilead Sciences Long-Acting HIV-1 Inhibitors Product Offered
11.3.3 Gilead Sciences Long-Acting HIV-1 Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Gilead Sciences Main Business Overview
11.3.5 Gilead Sciences Latest Developments
11.4 ViiV Healthcare
11.4.1 ViiV Healthcare Company Information
11.4.2 ViiV Healthcare Long-Acting HIV-1 Inhibitors Product Offered
11.4.3 ViiV Healthcare Long-Acting HIV-1 Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 ViiV Healthcare Main Business Overview
11.4.5 ViiV Healthcare Latest Developments
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Information
11.5.2 Johnson & Johnson Long-Acting HIV-1 Inhibitors Product Offered
11.5.3 Johnson & Johnson Long-Acting HIV-1 Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Johnson & Johnson Main Business Overview
11.5.5 Johnson & Johnson Latest Developments
11.6 MSD
11.6.1 MSD Company Information
11.6.2 MSD Long-Acting HIV-1 Inhibitors Product Offered
11.6.3 MSD Long-Acting HIV-1 Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 MSD Main Business Overview
11.6.5 MSD Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Long-Acting HIV-1 Inhibitors Market Size (2021-2032)
2.1.2 Long-Acting HIV-1 Inhibitors Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Long-Acting HIV-1 Inhibitors by Country/Region (2021, 2025 & 2032)
2.2 Long-Acting HIV-1 Inhibitors Segment by Type
2.2.1 Long-Acting Injection
2.2.2 Long-Acting Oral
2.2.3 Long-Acting HIV-1 Inhibitors Market Size by Type
2.2.3.1 Long-Acting HIV-1 Inhibitors Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global Long-Acting HIV-1 Inhibitors Market Size Market Share by Type (2021-2026)
2.3 Long-Acting HIV-1 Inhibitors Segment by Application
2.3.1 Hospital
2.3.2 Clinic
2.3.3 Others
2.3.4 Long-Acting HIV-1 Inhibitors Market Size by Application
2.3.4.1 Long-Acting HIV-1 Inhibitors Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global Long-Acting HIV-1 Inhibitors Market Size Market Share by Application (2021-2026)
3 LONG-ACTING HIV-1 INHIBITORS MARKET SIZE BY PLAYER
3.1 Long-Acting HIV-1 Inhibitors Market Size Market Share by Player
3.1.1 Global Long-Acting HIV-1 Inhibitors Revenue by Player (2021-2026)
3.1.2 Global Long-Acting HIV-1 Inhibitors Revenue Market Share by Player (2021-2026)
3.2 Global Long-Acting HIV-1 Inhibitors Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 LONG-ACTING HIV-1 INHIBITORS BY REGION
4.1 Long-Acting HIV-1 Inhibitors Market Size by Region (2021-2026)
4.2 Global Long-Acting HIV-1 Inhibitors Annual Revenue by Country/Region (2021-2026)
4.3 Americas Long-Acting HIV-1 Inhibitors Market Size Growth (2021-2026)
4.4 APAC Long-Acting HIV-1 Inhibitors Market Size Growth (2021-2026)
4.5 Europe Long-Acting HIV-1 Inhibitors Market Size Growth (2021-2026)
4.6 Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Long-Acting HIV-1 Inhibitors Market Size by Country (2021-2026)
5.2 Americas Long-Acting HIV-1 Inhibitors Market Size by Type (2021-2026)
5.3 Americas Long-Acting HIV-1 Inhibitors Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Long-Acting HIV-1 Inhibitors Market Size by Region (2021-2026)
6.2 APAC Long-Acting HIV-1 Inhibitors Market Size by Type (2021-2026)
6.3 APAC Long-Acting HIV-1 Inhibitors Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Long-Acting HIV-1 Inhibitors Market Size by Country (2021-2026)
7.2 Europe Long-Acting HIV-1 Inhibitors Market Size by Type (2021-2026)
7.3 Europe Long-Acting HIV-1 Inhibitors Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Long-Acting HIV-1 Inhibitors by Region (2021-2026)
8.2 Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size by Type (2021-2026)
8.3 Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL LONG-ACTING HIV-1 INHIBITORS MARKET FORECAST
10.1 Global Long-Acting HIV-1 Inhibitors Forecast by Region (2027-2032)
10.1.1 Global Long-Acting HIV-1 Inhibitors Forecast by Region (2027-2032)
10.1.2 Americas Long-Acting HIV-1 Inhibitors Forecast
10.1.3 APAC Long-Acting HIV-1 Inhibitors Forecast
10.1.4 Europe Long-Acting HIV-1 Inhibitors Forecast
10.1.5 Middle East & Africa Long-Acting HIV-1 Inhibitors Forecast
10.2 Americas Long-Acting HIV-1 Inhibitors Forecast by Country (2027-2032)
10.2.1 United States Market Long-Acting HIV-1 Inhibitors Forecast
10.2.2 Canada Market Long-Acting HIV-1 Inhibitors Forecast
10.2.3 Mexico Market Long-Acting HIV-1 Inhibitors Forecast
10.2.4 Brazil Market Long-Acting HIV-1 Inhibitors Forecast
10.3 APAC Long-Acting HIV-1 Inhibitors Forecast by Region (2027-2032)
10.3.1 China Long-Acting HIV-1 Inhibitors Market Forecast
10.3.2 Japan Market Long-Acting HIV-1 Inhibitors Forecast
10.3.3 Korea Market Long-Acting HIV-1 Inhibitors Forecast
10.3.4 Southeast Asia Market Long-Acting HIV-1 Inhibitors Forecast
10.3.5 India Market Long-Acting HIV-1 Inhibitors Forecast
10.3.6 Australia Market Long-Acting HIV-1 Inhibitors Forecast
10.4 Europe Long-Acting HIV-1 Inhibitors Forecast by Country (2027-2032)
10.4.1 Germany Market Long-Acting HIV-1 Inhibitors Forecast
10.4.2 France Market Long-Acting HIV-1 Inhibitors Forecast
10.4.3 UK Market Long-Acting HIV-1 Inhibitors Forecast
10.4.4 Italy Market Long-Acting HIV-1 Inhibitors Forecast
10.4.5 Russia Market Long-Acting HIV-1 Inhibitors Forecast
10.5 Middle East & Africa Long-Acting HIV-1 Inhibitors Forecast by Region (2027-2032)
10.5.1 Egypt Market Long-Acting HIV-1 Inhibitors Forecast
10.5.2 South Africa Market Long-Acting HIV-1 Inhibitors Forecast
10.5.3 Israel Market Long-Acting HIV-1 Inhibitors Forecast
10.5.4 Turkey Market Long-Acting HIV-1 Inhibitors Forecast
10.6 Global Long-Acting HIV-1 Inhibitors Forecast by Type (2027-2032)
10.7 Global Long-Acting HIV-1 Inhibitors Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Long-Acting HIV-1 Inhibitors Forecast
11 KEY PLAYERS ANALYSIS
11.1 GSK
11.1.1 GSK Company Information
11.1.2 GSK Long-Acting HIV-1 Inhibitors Product Offered
11.1.3 GSK Long-Acting HIV-1 Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 GSK Main Business Overview
11.1.5 GSK Latest Developments
11.2 Frontier Biotechnologies
11.2.1 Frontier Biotechnologies Company Information
11.2.2 Frontier Biotechnologies Long-Acting HIV-1 Inhibitors Product Offered
11.2.3 Frontier Biotechnologies Long-Acting HIV-1 Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Frontier Biotechnologies Main Business Overview
11.2.5 Frontier Biotechnologies Latest Developments
11.3 Gilead Sciences
11.3.1 Gilead Sciences Company Information
11.3.2 Gilead Sciences Long-Acting HIV-1 Inhibitors Product Offered
11.3.3 Gilead Sciences Long-Acting HIV-1 Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Gilead Sciences Main Business Overview
11.3.5 Gilead Sciences Latest Developments
11.4 ViiV Healthcare
11.4.1 ViiV Healthcare Company Information
11.4.2 ViiV Healthcare Long-Acting HIV-1 Inhibitors Product Offered
11.4.3 ViiV Healthcare Long-Acting HIV-1 Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 ViiV Healthcare Main Business Overview
11.4.5 ViiV Healthcare Latest Developments
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Information
11.5.2 Johnson & Johnson Long-Acting HIV-1 Inhibitors Product Offered
11.5.3 Johnson & Johnson Long-Acting HIV-1 Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Johnson & Johnson Main Business Overview
11.5.5 Johnson & Johnson Latest Developments
11.6 MSD
11.6.1 MSD Company Information
11.6.2 MSD Long-Acting HIV-1 Inhibitors Product Offered
11.6.3 MSD Long-Acting HIV-1 Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 MSD Main Business Overview
11.6.5 MSD Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Long-Acting HIV-1 Inhibitors Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Long-Acting HIV-1 Inhibitors Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Long-Acting Injection
Table 4. Major Players of Long-Acting Oral
Table 5. Long-Acting HIV-1 Inhibitors Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Long-Acting HIV-1 Inhibitors Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Long-Acting HIV-1 Inhibitors Market Size Market Share by Type (2021-2026)
Table 8. Long-Acting HIV-1 Inhibitors Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Long-Acting HIV-1 Inhibitors Market Size by Application (2021-2026) & ($ millions)
Table 10. Global Long-Acting HIV-1 Inhibitors Market Size Market Share by Application (2021-2026)
Table 11. Global Long-Acting HIV-1 Inhibitors Revenue by Player (2021-2026) & ($ millions)
Table 12. Global Long-Acting HIV-1 Inhibitors Revenue Market Share by Player (2021-2026)
Table 13. Long-Acting HIV-1 Inhibitors Key Players Head office and Products Offered
Table 14. Long-Acting HIV-1 Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Long-Acting HIV-1 Inhibitors Market Size by Region (2021-2026) & ($ millions)
Table 18. Global Long-Acting HIV-1 Inhibitors Market Size Market Share by Region (2021-2026)
Table 19. Global Long-Acting HIV-1 Inhibitors Revenue by Country/Region (2021-2026) & ($ millions)
Table 20. Global Long-Acting HIV-1 Inhibitors Revenue Market Share by Country/Region (2021-2026)
Table 21. Americas Long-Acting HIV-1 Inhibitors Market Size by Country (2021-2026) & ($ millions)
Table 22. Americas Long-Acting HIV-1 Inhibitors Market Size Market Share by Country (2021-2026)
Table 23. Americas Long-Acting HIV-1 Inhibitors Market Size by Type (2021-2026) & ($ millions)
Table 24. Americas Long-Acting HIV-1 Inhibitors Market Size Market Share by Type (2021-2026)
Table 25. Americas Long-Acting HIV-1 Inhibitors Market Size by Application (2021-2026) & ($ millions)
Table 26. Americas Long-Acting HIV-1 Inhibitors Market Size Market Share by Application (2021-2026)
Table 27. APAC Long-Acting HIV-1 Inhibitors Market Size by Region (2021-2026) & ($ millions)
Table 28. APAC Long-Acting HIV-1 Inhibitors Market Size Market Share by Region (2021-2026)
Table 29. APAC Long-Acting HIV-1 Inhibitors Market Size by Type (2021-2026) & ($ millions)
Table 30. APAC Long-Acting HIV-1 Inhibitors Market Size by Application (2021-2026) & ($ millions)
Table 31. Europe Long-Acting HIV-1 Inhibitors Market Size by Country (2021-2026) & ($ millions)
Table 32. Europe Long-Acting HIV-1 Inhibitors Market Size Market Share by Country (2021-2026)
Table 33. Europe Long-Acting HIV-1 Inhibitors Market Size by Type (2021-2026) & ($ millions)
Table 34. Europe Long-Acting HIV-1 Inhibitors Market Size by Application (2021-2026) & ($ millions)
Table 35. Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size by Region (2021-2026) & ($ millions)
Table 36. Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size by Type (2021-2026) & ($ millions)
Table 37. Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size by Application (2021-2026) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Long-Acting HIV-1 Inhibitors
Table 39. Key Market Challenges & Risks of Long-Acting HIV-1 Inhibitors
Table 40. Key Industry Trends of Long-Acting HIV-1 Inhibitors
Table 41. Global Long-Acting HIV-1 Inhibitors Market Size Forecast by Region (2027-2032) & ($ millions)
Table 42. Global Long-Acting HIV-1 Inhibitors Market Size Market Share Forecast by Region (2027-2032)
Table 43. Global Long-Acting HIV-1 Inhibitors Market Size Forecast by Type (2027-2032) & ($ millions)
Table 44. Global Long-Acting HIV-1 Inhibitors Market Size Forecast by Application (2027-2032) & ($ millions)
Table 45. GSK Details, Company Type, Long-Acting HIV-1 Inhibitors Area Served and Its Competitors
Table 46. GSK Long-Acting HIV-1 Inhibitors Product Offered
Table 47. GSK Long-Acting HIV-1 Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 48. GSK Main Business
Table 49. GSK Latest Developments
Table 50. Frontier Biotechnologies Details, Company Type, Long-Acting HIV-1 Inhibitors Area Served and Its Competitors
Table 51. Frontier Biotechnologies Long-Acting HIV-1 Inhibitors Product Offered
Table 52. Frontier Biotechnologies Long-Acting HIV-1 Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 53. Frontier Biotechnologies Main Business
Table 54. Frontier Biotechnologies Latest Developments
Table 55. Gilead Sciences Details, Company Type, Long-Acting HIV-1 Inhibitors Area Served and Its Competitors
Table 56. Gilead Sciences Long-Acting HIV-1 Inhibitors Product Offered
Table 57. Gilead Sciences Long-Acting HIV-1 Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 58. Gilead Sciences Main Business
Table 59. Gilead Sciences Latest Developments
Table 60. ViiV Healthcare Details, Company Type, Long-Acting HIV-1 Inhibitors Area Served and Its Competitors
Table 61. ViiV Healthcare Long-Acting HIV-1 Inhibitors Product Offered
Table 62. ViiV Healthcare Long-Acting HIV-1 Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. ViiV Healthcare Main Business
Table 64. ViiV Healthcare Latest Developments
Table 65. Johnson & Johnson Details, Company Type, Long-Acting HIV-1 Inhibitors Area Served and Its Competitors
Table 66. Johnson & Johnson Long-Acting HIV-1 Inhibitors Product Offered
Table 67. Johnson & Johnson Long-Acting HIV-1 Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Johnson & Johnson Main Business
Table 69. Johnson & Johnson Latest Developments
Table 70. MSD Details, Company Type, Long-Acting HIV-1 Inhibitors Area Served and Its Competitors
Table 71. MSD Long-Acting HIV-1 Inhibitors Product Offered
Table 72. MSD Long-Acting HIV-1 Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. MSD Main Business
Table 74. MSD Latest Developments
Table 1. Long-Acting HIV-1 Inhibitors Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Long-Acting HIV-1 Inhibitors Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Long-Acting Injection
Table 4. Major Players of Long-Acting Oral
Table 5. Long-Acting HIV-1 Inhibitors Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Long-Acting HIV-1 Inhibitors Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Long-Acting HIV-1 Inhibitors Market Size Market Share by Type (2021-2026)
Table 8. Long-Acting HIV-1 Inhibitors Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Long-Acting HIV-1 Inhibitors Market Size by Application (2021-2026) & ($ millions)
Table 10. Global Long-Acting HIV-1 Inhibitors Market Size Market Share by Application (2021-2026)
Table 11. Global Long-Acting HIV-1 Inhibitors Revenue by Player (2021-2026) & ($ millions)
Table 12. Global Long-Acting HIV-1 Inhibitors Revenue Market Share by Player (2021-2026)
Table 13. Long-Acting HIV-1 Inhibitors Key Players Head office and Products Offered
Table 14. Long-Acting HIV-1 Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Long-Acting HIV-1 Inhibitors Market Size by Region (2021-2026) & ($ millions)
Table 18. Global Long-Acting HIV-1 Inhibitors Market Size Market Share by Region (2021-2026)
Table 19. Global Long-Acting HIV-1 Inhibitors Revenue by Country/Region (2021-2026) & ($ millions)
Table 20. Global Long-Acting HIV-1 Inhibitors Revenue Market Share by Country/Region (2021-2026)
Table 21. Americas Long-Acting HIV-1 Inhibitors Market Size by Country (2021-2026) & ($ millions)
Table 22. Americas Long-Acting HIV-1 Inhibitors Market Size Market Share by Country (2021-2026)
Table 23. Americas Long-Acting HIV-1 Inhibitors Market Size by Type (2021-2026) & ($ millions)
Table 24. Americas Long-Acting HIV-1 Inhibitors Market Size Market Share by Type (2021-2026)
Table 25. Americas Long-Acting HIV-1 Inhibitors Market Size by Application (2021-2026) & ($ millions)
Table 26. Americas Long-Acting HIV-1 Inhibitors Market Size Market Share by Application (2021-2026)
Table 27. APAC Long-Acting HIV-1 Inhibitors Market Size by Region (2021-2026) & ($ millions)
Table 28. APAC Long-Acting HIV-1 Inhibitors Market Size Market Share by Region (2021-2026)
Table 29. APAC Long-Acting HIV-1 Inhibitors Market Size by Type (2021-2026) & ($ millions)
Table 30. APAC Long-Acting HIV-1 Inhibitors Market Size by Application (2021-2026) & ($ millions)
Table 31. Europe Long-Acting HIV-1 Inhibitors Market Size by Country (2021-2026) & ($ millions)
Table 32. Europe Long-Acting HIV-1 Inhibitors Market Size Market Share by Country (2021-2026)
Table 33. Europe Long-Acting HIV-1 Inhibitors Market Size by Type (2021-2026) & ($ millions)
Table 34. Europe Long-Acting HIV-1 Inhibitors Market Size by Application (2021-2026) & ($ millions)
Table 35. Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size by Region (2021-2026) & ($ millions)
Table 36. Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size by Type (2021-2026) & ($ millions)
Table 37. Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size by Application (2021-2026) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Long-Acting HIV-1 Inhibitors
Table 39. Key Market Challenges & Risks of Long-Acting HIV-1 Inhibitors
Table 40. Key Industry Trends of Long-Acting HIV-1 Inhibitors
Table 41. Global Long-Acting HIV-1 Inhibitors Market Size Forecast by Region (2027-2032) & ($ millions)
Table 42. Global Long-Acting HIV-1 Inhibitors Market Size Market Share Forecast by Region (2027-2032)
Table 43. Global Long-Acting HIV-1 Inhibitors Market Size Forecast by Type (2027-2032) & ($ millions)
Table 44. Global Long-Acting HIV-1 Inhibitors Market Size Forecast by Application (2027-2032) & ($ millions)
Table 45. GSK Details, Company Type, Long-Acting HIV-1 Inhibitors Area Served and Its Competitors
Table 46. GSK Long-Acting HIV-1 Inhibitors Product Offered
Table 47. GSK Long-Acting HIV-1 Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 48. GSK Main Business
Table 49. GSK Latest Developments
Table 50. Frontier Biotechnologies Details, Company Type, Long-Acting HIV-1 Inhibitors Area Served and Its Competitors
Table 51. Frontier Biotechnologies Long-Acting HIV-1 Inhibitors Product Offered
Table 52. Frontier Biotechnologies Long-Acting HIV-1 Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 53. Frontier Biotechnologies Main Business
Table 54. Frontier Biotechnologies Latest Developments
Table 55. Gilead Sciences Details, Company Type, Long-Acting HIV-1 Inhibitors Area Served and Its Competitors
Table 56. Gilead Sciences Long-Acting HIV-1 Inhibitors Product Offered
Table 57. Gilead Sciences Long-Acting HIV-1 Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 58. Gilead Sciences Main Business
Table 59. Gilead Sciences Latest Developments
Table 60. ViiV Healthcare Details, Company Type, Long-Acting HIV-1 Inhibitors Area Served and Its Competitors
Table 61. ViiV Healthcare Long-Acting HIV-1 Inhibitors Product Offered
Table 62. ViiV Healthcare Long-Acting HIV-1 Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. ViiV Healthcare Main Business
Table 64. ViiV Healthcare Latest Developments
Table 65. Johnson & Johnson Details, Company Type, Long-Acting HIV-1 Inhibitors Area Served and Its Competitors
Table 66. Johnson & Johnson Long-Acting HIV-1 Inhibitors Product Offered
Table 67. Johnson & Johnson Long-Acting HIV-1 Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Johnson & Johnson Main Business
Table 69. Johnson & Johnson Latest Developments
Table 70. MSD Details, Company Type, Long-Acting HIV-1 Inhibitors Area Served and Its Competitors
Table 71. MSD Long-Acting HIV-1 Inhibitors Product Offered
Table 72. MSD Long-Acting HIV-1 Inhibitors Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. MSD Main Business
Table 74. MSD Latest Developments
LIST OF FIGURES
Figure 1. Long-Acting HIV-1 Inhibitors Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Long-Acting HIV-1 Inhibitors Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Long-Acting HIV-1 Inhibitors Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Long-Acting HIV-1 Inhibitors Sales Market Share by Country/Region (2025)
Figure 8. Long-Acting HIV-1 Inhibitors Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Long-Acting HIV-1 Inhibitors Market Size Market Share by Type in 2025
Figure 10. Long-Acting HIV-1 Inhibitors in Hospital
Figure 11. Global Long-Acting HIV-1 Inhibitors Market: Hospital (2021-2026) & ($ millions)
Figure 12. Long-Acting HIV-1 Inhibitors in Clinic
Figure 13. Global Long-Acting HIV-1 Inhibitors Market: Clinic (2021-2026) & ($ millions)
Figure 14. Long-Acting HIV-1 Inhibitors in Others
Figure 15. Global Long-Acting HIV-1 Inhibitors Market: Others (2021-2026) & ($ millions)
Figure 16. Global Long-Acting HIV-1 Inhibitors Market Size Market Share by Application in 2025
Figure 17. Global Long-Acting HIV-1 Inhibitors Revenue Market Share by Player in 2025
Figure 18. Global Long-Acting HIV-1 Inhibitors Market Size Market Share by Region (2021-2026)
Figure 19. Americas Long-Acting HIV-1 Inhibitors Market Size 2021-2026 ($ millions)
Figure 20. APAC Long-Acting HIV-1 Inhibitors Market Size 2021-2026 ($ millions)
Figure 21. Europe Long-Acting HIV-1 Inhibitors Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size 2021-2026 ($ millions)
Figure 23. Americas Long-Acting HIV-1 Inhibitors Value Market Share by Country in 2025
Figure 24. United States Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Long-Acting HIV-1 Inhibitors Market Size Market Share by Region in 2025
Figure 29. APAC Long-Acting HIV-1 Inhibitors Market Size Market Share by Type (2021-2026)
Figure 30. APAC Long-Acting HIV-1 Inhibitors Market Size Market Share by Application (2021-2026)
Figure 31. China Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 35. India Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Long-Acting HIV-1 Inhibitors Market Size Market Share by Country in 2025
Figure 38. Europe Long-Acting HIV-1 Inhibitors Market Size Market Share by Type (2021-2026)
Figure 39. Europe Long-Acting HIV-1 Inhibitors Market Size Market Share by Application (2021-2026)
Figure 40. Germany Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 41. France Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 54. APAC Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 55. Europe Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 57. United States Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 58. Canada Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 59. Mexico Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 60. Brazil Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 61. China Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 62. Japan Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 63. Korea Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 65. India Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 66. Australia Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 67. Germany Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 68. France Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 69. UK Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 70. Italy Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 71. Russia Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 72. Egypt Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 73. South Africa Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 74. Israel Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 75. Turkey Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 76. Global Long-Acting HIV-1 Inhibitors Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Long-Acting HIV-1 Inhibitors Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 1. Long-Acting HIV-1 Inhibitors Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Long-Acting HIV-1 Inhibitors Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Long-Acting HIV-1 Inhibitors Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Long-Acting HIV-1 Inhibitors Sales Market Share by Country/Region (2025)
Figure 8. Long-Acting HIV-1 Inhibitors Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Long-Acting HIV-1 Inhibitors Market Size Market Share by Type in 2025
Figure 10. Long-Acting HIV-1 Inhibitors in Hospital
Figure 11. Global Long-Acting HIV-1 Inhibitors Market: Hospital (2021-2026) & ($ millions)
Figure 12. Long-Acting HIV-1 Inhibitors in Clinic
Figure 13. Global Long-Acting HIV-1 Inhibitors Market: Clinic (2021-2026) & ($ millions)
Figure 14. Long-Acting HIV-1 Inhibitors in Others
Figure 15. Global Long-Acting HIV-1 Inhibitors Market: Others (2021-2026) & ($ millions)
Figure 16. Global Long-Acting HIV-1 Inhibitors Market Size Market Share by Application in 2025
Figure 17. Global Long-Acting HIV-1 Inhibitors Revenue Market Share by Player in 2025
Figure 18. Global Long-Acting HIV-1 Inhibitors Market Size Market Share by Region (2021-2026)
Figure 19. Americas Long-Acting HIV-1 Inhibitors Market Size 2021-2026 ($ millions)
Figure 20. APAC Long-Acting HIV-1 Inhibitors Market Size 2021-2026 ($ millions)
Figure 21. Europe Long-Acting HIV-1 Inhibitors Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size 2021-2026 ($ millions)
Figure 23. Americas Long-Acting HIV-1 Inhibitors Value Market Share by Country in 2025
Figure 24. United States Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Long-Acting HIV-1 Inhibitors Market Size Market Share by Region in 2025
Figure 29. APAC Long-Acting HIV-1 Inhibitors Market Size Market Share by Type (2021-2026)
Figure 30. APAC Long-Acting HIV-1 Inhibitors Market Size Market Share by Application (2021-2026)
Figure 31. China Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 35. India Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Long-Acting HIV-1 Inhibitors Market Size Market Share by Country in 2025
Figure 38. Europe Long-Acting HIV-1 Inhibitors Market Size Market Share by Type (2021-2026)
Figure 39. Europe Long-Acting HIV-1 Inhibitors Market Size Market Share by Application (2021-2026)
Figure 40. Germany Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 41. France Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Long-Acting HIV-1 Inhibitors Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 54. APAC Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 55. Europe Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 57. United States Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 58. Canada Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 59. Mexico Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 60. Brazil Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 61. China Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 62. Japan Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 63. Korea Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 65. India Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 66. Australia Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 67. Germany Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 68. France Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 69. UK Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 70. Italy Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 71. Russia Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 72. Egypt Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 73. South Africa Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 74. Israel Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 75. Turkey Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)
Figure 76. Global Long-Acting HIV-1 Inhibitors Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Long-Acting HIV-1 Inhibitors Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Long-Acting HIV-1 Inhibitors Market Size 2027-2032 ($ millions)